Jhangiani, Haresh

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 643

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting

Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H.-M., & Baranowski, V. (2007) · Current Medical Research and Opinion

Nausea and vomiting managementPregnancy and Medication Impact

Cited by 214

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Hurvitz, S. A., Dalenc, F., Campone, M., O’Regan, R. M., Tjan-Heijnen, V. C., Gligorov, J., Llombart, A., Jhangiani, H., Mirshahidi, H. R., Tan-Chiu, E., et al. (2013) · Breast Cancer Research and Treatment

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 76

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48